Loading
A phase 3 trial of Iparomlimab and tuvonralimab in Small-cell lung cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.
a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy is a phase 3 interventional study registered as NCT06789796 by Qilu Pharmaceutical Co., Ltd., with 636 participants planned, started 2025-02 and due to reach its primary completion in 2028-03. Interventions recorded: Iparomlimab and Tuvonralimab (QL1706), placebo for QL1604, QL1604, placebo for Iparomlimab and Tuvonralimab (QL1706). Conditions recorded: Small-cell Lung Cancer.
Linked to the drug Iparomlimab and tuvonralimab because the registry names it among its interventions and Small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iparomlimab and tuvonralimab and the tag pipeline.
Shares Iparomlimab and tuvonralimab and the tag pipeline.
Shares Limited-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/